Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0590 CAR T in Relapsed/Refractory Multiple Myeloma
NCT05066022Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT0590 in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Incidence of Dose-Limiting Toxicity at 28 days. Status: unknown.
02
Drugs
CT0590
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05066022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05066022.